Aldeyra Therapeutics ($ALDX) Reproxalap Clinical Trial Results Case

Investors can submit applications for the lead plaintiff role.

D. Massachusetts

Court

1:26-cv-11510

Case number

11/03/2023

Class period Start

03/16/2026

Class period End

05/29/2026

Lead Plaintiff motion deadline

$ALDX investors filed a claim against Aldeyra Therapeutics for allegedly overstating the strength and reliability of reproxalap clinical trial results for dry eye disease.
After Aldeyra Therapeutics disclosed that the FDA said the application lacked substantial evidence of efficacy and that inconsistent study results undermined the reliability of the positive findings, $ALDX fell 70.7% on March 17, 2026.
$ALDX investors can join this case to be notified about potential recovery.
Case Details:

Between November 3, 2023, and March 16, 2026, Aldeyra Therapeutics told investors that reproxalap had shown broad-based, rapid-onset activity and consistent safety in Phase 2 and Phase 3 trials for dry eye disease. Executives emphasized that the drug’s results were statistically significant, clinically relevant, and supported the company’s platform and prospects.

However, during this period, investors alleged that the underlying trial results were inconsistent and did not support those positive statements. Aldeyra Therapeutics allegedly failed to disclose that the reproxalap trial results were inconsistent. This inconsistency rendered the positive findings unreliable and meaningless, and the company’s statements about reproxalap’s effectiveness and prospects lacked a reasonable basis.

Then, on March 17, 2026, the company disclosed that it had received an FDA Complete Response Letter stating there was a lack of substantial evidence that reproxalap would work as proposed and that the application failed to demonstrate efficacy for the signs and symptoms of dry eye disease. $ALDX fell $2.99, closing at $1.24. 

Additional revelations followed on March 17, 2026, including the FDA’s statement that inconsistent study results raised serious concerns about the reliability and meaningfulness of the positive findings. 

By March 17, 2026, shares had dropped to $1.24, representing a 70.7% decline during the correction period.

Based on these events, $ALDX investors filed a claim against Aldeyra Therapeutics, alleging the company:
It overstated reproxalap’s trial results.
It presented inconsistent clinical findings as reliable, meaningful evidence that the drug was effective for dry eye disease.
It misled investors about reproxalap’s prospects until the FDA rejection exposed the weakness of the evidence and caused losses.
Investors argue Aldeyra Therapeutics misled the market about the reliability and significance of reproxalap’s clinical data, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

03/17/2026

Filing date

03/30/2026

Lead Plaintiff Deadline

05/29/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.